Current:Home > StocksBayer makes a deal on popular contraceptive with Mark Cuban's online pharmacy -Trailblazer Wealth Guides
Bayer makes a deal on popular contraceptive with Mark Cuban's online pharmacy
View
Date:2025-04-26 08:48:06
Bayer is the latest name-brand drugmaker to dip its toe into the world of Mark Cuban's online pharmacy, Cost Plus Drugs.
The website offers drugs at steep discounts bypassing middlemen called pharmacy benefit managers. It mostly sells generics, but has been slowly adding brand name products as well.
Yaz birth control pills and Climara, a hormone patch for menopause, will both now be available for a fraction of their list prices, including Cost Plus's standard 15% markup and shipping.
"As I look at our partnership with Cost Plus, I really look at this as a test and learn," says Sebastian Guth, president of U.S. Pharmaceuticals at Bayer. "It's a first initial step. We will learn and see what the results of this partnership are and may then decide to expand it further."
The brand name drugs are both off-patent and face generic competition, including within Cost Plus, where the generics are even less expensive than the discounted name-brand options. But Guth says women often pay for both these drugs out of pocket, skipping their insurance. And they often prefer to use the brand name over available generics.
The Cost Plus partnership, he says, will expand access to patients.
Health insurance usually covers birth control
But according to Laurie Sobel, associate director of women's health policy at nonprofit KFF, the benefit of the new arrangement for patients isn't clear.
Under the Affordable Care Act, birth control pills like Yaz are usually covered without any copay as long as the pharmacy and provider are in the insurance plan's network, though some plans may only cover the generic.
But not everyone knows that.
"We know from our survey from 2022 that about 40% of females are not aware of that," Sobel says. "So there's a knowledge gap of who knows that if they use their insurance, it would be covered."
In fact, Yaz is in the top 10 oral contraceptives people paid for despite the Affordable Care Act rules. "And we also know that it's been highly marketed... Yaz was the most advertised brand," she said, citing a study by Harvard researchers.
So even though Yaz will have a $117 dollar price tag at Cost Plus for a three-month supply compared to its $515 list price, it would still be a lot cheaper to just get the generic through insurance without a copay.
Some consumers prefer to pay cash
A Cost Plus Drugs spokesperson wrote in an email to NPR that most of the company's business is from cash-paying customers who skip their insurance, but the number of users whose insurance includes Cost Plus is "growing quickly."
For those paying cash, Climara is also much cheaper at Cost Plus — $53 instead of $76 list price.
Those higher list prices don't take into account what drug companies actually get paid for medicines when they're purchased through insurance under normal circumstances.
Middlemen called pharmacy benefit managers get a cut, too, and the drug companies are left with a net price.
Drug industry veteran Richard Evans, general manager of SSR Health, says the company probably isn't making less money through Cost Plus than regular insurance.
Guth declined to share Yaz's or Climara's net prices.
Mark Cuban's pharmacy could boost the drugs' sales. It will probably take a few months to see how the experiment works out.
veryGood! (2)
Related
- The FTC says 'gamified' online job scams by WhatsApp and text on the rise. What to know.
- Dog that walks on hind legs after accident inspires audiences
- Gallaudet University holds graduation ceremony for segregated Black deaf students and teachers
- Businesses face more and more pressure from investors to act on climate change
- Warm inflation data keep S&P 500, Dow, Nasdaq under wraps before Fed meeting next week
- Lime Crime Temporary Hair Dye & Makeup Can Make It Your Hottest Summer Yet
- In the Latest Rights of Nature Case, a Tribe Is Suing Seattle on Behalf of Salmon in the Skagit River
- Gallaudet University holds graduation ceremony for segregated Black deaf students and teachers
- Macy's says employee who allegedly hid $150 million in expenses had no major 'impact'
- Climate Change Poses a Huge Threat to Railroads. Environmental Engineers Have Ideas for How to Combat That
Ranking
- Bill Belichick's salary at North Carolina: School releases football coach's contract details
- A Florida Chemical Plant Has Fallen Behind in Its Pledge to Cut Emissions of a Potent Greenhouse Gas
- Gallaudet University holds graduation ceremony for segregated Black deaf students and teachers
- Earth Has a 50-50 Chance of Hitting a Grim Global Warming Milestone in the Next Five Years
- The FBI should have done more to collect intelligence before the Capitol riot, watchdog finds
- Naomi Campbell Welcomes Baby No. 2
- The Fed's radical new bank band-aid
- Proof Pregnant Kourtney Kardashian and Travis Barker Already Chose Their Baby Boy’s Name
Recommendation
Highlights from Trump’s interview with Time magazine
Behati Prinsloo Shares Glimpse Inside Family Trip to Paris With Adam Levine and Their 3 Kids
SpaceX prepares to launch its mammoth rocket 'Starship'
The big reason why the U.S. is seeking the toughest-ever rules for vehicle emissions
Whoopi Goldberg is delightfully vile as Miss Hannigan in ‘Annie’ stage return
A Florida Chemical Plant Has Fallen Behind in Its Pledge to Cut Emissions of a Potent Greenhouse Gas
Why sanctions don't work — but could if done right
Inside Clean Energy: Here’s Why Some Utilities Support, and Others Are Wary of, the Federal Clean Energy Proposal